Zelira Therapeutics Limited ZLDAF OTC

Other OTC • Healthcare • Biotechnology • AU • USD

SharesGrow Score

5/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Zelira Therapeutics Limited (ZLDAF) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 5/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

5/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

0/100

→ Income

✗

GROWTH

15/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — ZLDAF

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio5,747.17

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-0.32

Book Value / Share$0.00

Revenue / Share$0.00

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-1.39	$300K	$-898.64K	-299.5%
2017	$-2.18	$100.04K	$-6.16M	-6154.8%
2018	$-0.40	$313.76K	$-1.73M	-551.3%
2019	$-0.83	$769.03K	$-3.57M	-463.9%
2020	$-1.45	$0.00	$-7.02M	-
2021	$-1.29	$663.32K	$-8.55M	-1288.8%
2022	$-1.49	$1.54M	$-11.95M	-775.4%
2023	$-0.55	$301.12K	$-5.57M	-1850.8%
2024	$-3.22	$94.95K	$-36.57M	-38513%
2025	$-0.32	$656.00	$-3.63M	-553029.3%